Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer. 

Tan previously served as iX Biopharma’s director of corporate and commercial strategy since 2019, and commercial director from 2017 to 2019.

As director of corporate and commercial strategy, Tan developed, communicated and executed corporate and commercial strategic initiatives of the iX Group.

SEE: iX Biopharma obtains approval and registration of male erectile dysfunction drug in Singapore

According to iX Biopharma’s website, Tan was a corporate lawyer at Wong Partnership prior to joining iX Biopharma, where she specialised in the capital markets practice. 

She was involved in numerous local and international IPOs, including the listing of iX Biopharma Ltd on the SGX Catalist in 2015. 

She has also had extensive experience advising on a broad range of local and cross border mergers and acquisitions and other corporate transactions.

Shares of iX Biopharma closed at 26 cents on 18 Jan, 1 cent higher than the day before.